Fundz

Garuda Therapeutics reported raising $47.7 Million in an initial SEC Form D filing

PRIVATEOct 31, 2024

Amount Raised

$47.7 Million

$47.7 Million sold, per SEC Form D (first sale Oct 17, 2024)

Round Type

Venture

CambridgeBiotechnologyHealth CareScience And Engineering

Investors

Kyowa Kirin Co

Who else raised in Science And Engineering and Biotechnology around the same time

Companies in the same sectors as Garuda Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • MAIA Biotechnology raised $2.4M (Seed) on October 28, 2024.
  • MAIA Biotechnology raised $2.4M (Seed) on October 28, 2024.
  • Agomab raised $89M (Series D) on October 25, 2024.
  • 22nd Century raised $1.2M (Seed) on September 27, 2024.
  • PBS Biotech raised $8.5M on September 11, 2024.
  • Viome raised $25M (Series D) on September 10, 2024.

Who to call at Garuda Therapeutics, and when

A new round usually means Garuda Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Garuda Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Garuda Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Garuda Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Garuda Therapeutics

Location

215 First Street

Cambridge, Massachusetts, United States

About

Garuda Therapeutics seeks to eliminate the need for stem cell donors for blood stem cell transplants. Garuda’s proprietary off-the-shelf hematopoietic stem cell (HSC) therapies enable self-renewing, HLA compatible and transgene-free HSCs, available immediately for patients. An immediately available, off-the-shelf option for patients could provide much needed strategies in a multitude of blood disorders across oncology, autoimmune indications, rare heme disorders and inborn errors of metabolism by effectively resetting bone marrow function.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Garuda Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Garuda Therapeutics's next move

See what Strategic adds

Garuda Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.